

Notice of Allowability

Application No.

10/501,438

Examiner

Rosanne Kosson

Applicant(s)

BERTHA, ANDRAS

Art Unit

1652

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to an amendment filed on April 23, 2007.
2. ☒ The allowed claim(s) is/are 4 and 25-29.
3. ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some* c) ☐ None of the:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☒ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
- (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
- 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
- (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- | | |
|--|---|
| 1. <input type="checkbox"/> Notice of References Cited (PTO-892) | 5. <input type="checkbox"/> Notice of Informal Patent Application |
| 2. <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 6. <input type="checkbox"/> Interview Summary (PTO-413),
Paper No./Mail Date _____ |
| 3. <input type="checkbox"/> Information Disclosure Statements (PTO/SB/08),
Paper No./Mail Date _____ | 7. <input checked="" type="checkbox"/> Examiner's Amendment/Comment |
| 4. <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit
of Biological Material | 8. <input type="checkbox"/> Examiner's Statement of Reasons for Allowance |
| | 9. <input type="checkbox"/> Other _____ |

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

1. The application has been amended as follows.

The specification is amended as follows.

Insert the following paragraph after the title.

This application is the U.S. national phase of International Application No. PCT/HU03/00004, filed on January 15, 2003, which claims priority to Hungarian Application No. P0200172, filed on January 15, 2002.

The claims are amended as follows.

1-2. (canceled)

4. (currently amended) A method for obtaining an anti-tumor substance from the colostrum of an even-toed hoofed animal having leucosis, comprising the steps of:

- a) providing colostrum from an even-toed hoofed animal having leucosis;
- b) shaking the colostrum with an identical volume of a 1:1 mixture comprising i-propyl alcohol and chloroform ~~of identical volume~~ at room temperature for 8 hours;
- c) centrifuging the resulting material at a speed of at least 5000 rev/min for 20 minutes in a cooled state to result in an upper layer, medial layer, organic layer and the rest of the material;
- d) removing ~~selecting~~ the upper layer and subjecting it to freeze-drying; and
- e) diluting the dried upper layer in physiological saline solution to a therapeutically effective concentration of the anti-tumor substance.

27. (currently amended) The method of claim 4, further comprising:

- f) diluting the rest of the material obtained in step 4c) with a 1:1 mixture of chloroform and benzyl alcohol to make up the original volume and shaking the material for 8 hours;
- g) storing the material at a temperature of [[+]]2-4°C;
- h) centrifuging the material from step g) just as in step c) and separating the upper layer; and
- i) freeze drying the upper layer obtained in step h); and

Art Unit: 1652

j) diluting the dried upper layer in physiological saline solution to a therapeutically effective concentration of the anti-tumor substance antibody.

30-38. (canceled)

Authorization for this Examiner's Amendment was given by telephone by Applicants' agent, Mr. Barry Wilson, on May 8, 2007.

2. The following is an examiner's statement of reasons for allowance. The prior art neither teaches nor suggests the claimed method of isolating an anti-tumor substance from the colostrum of even-toed hoofed animals that have leukosis. As previously discussed, Janusz et al. (US 2005/0152985) disclose that mammalian colostrum contains an anti-tumor substance that may be used to treat humans, the polypeptide colostrinin, which has a number of biological activities, including cytokine activity (see paragraphs 1-3, 6, 7 and 44-47). But, the colostrinin of Janusz et al. is not isolated by the claimed method.

3. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Rosanne Kosson whose telephone number is 571-272-2923. The examiner can normally be reached on Monday-Friday, 8:30-6:00, alternate Mondays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1652

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Rosanne Kosson
Examiner, Art Unit 1652

rk/2007-05-08

Rosanne Kosson

Rebecca Lint
REBECCA E. LINT
PRIMARY EXAMINER
GROUP 1800
1600